COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Long Term Follow-up of Bone Mineral Density in Hormone Treated Turner Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00625001
Recruitment Status : Unknown
Verified February 2008 by University of Aarhus.
Recruitment status was:  Active, not recruiting
First Posted : February 28, 2008
Last Update Posted : February 28, 2008
Information provided by:
University of Aarhus

Brief Summary:

Turner Syndrome (TS) is associated with osteopenia and osteoporosis. Reduced bone mineral density (BMD) and increased risk of fractures are present in many younger and middle-aged women with TS. The objective is therefore to describe longitudinal changes in BMD in TS.

The study is an observational follow-up study. Examinations at baseline, after 5 and 10 years.

Bone mineral density is measured by dual energy x-ray absorptiometry (DEXA) and bone turnover by bone markers.

Main Outcome Measures: Bone mineral density (BMD; grams/ square centimetre) were measured at lumbar spine, hip and the non-dominant forearm.

Condition or disease
Turner Syndrome

Layout table for study information
Study Type : Observational
Actual Enrollment : 54 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Long Term Follow-up of Bone Mineral Density in Hormone Treated Turner Syndrome
Study Start Date : November 1994
Actual Primary Completion Date : October 1996
Estimated Study Completion Date : June 2010

Women with Turner syndrome
Healthy control women

Primary Outcome Measures :
  1. Bone Mineral Density in columna lumbalis, collum femoris and distal ulnae Bone mineral density (BMD; grams/ square centimetre) were measured at lumbar spine, hip and the non-dominant forearm. [ Time Frame: Evey 5 years ]

Biospecimen Retention:   Samples Without DNA
Blood samples

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Women with Turner syndrome

Inclusion Criteria:

  • Turner syndrome verified by karyotyping

Exclusion Criteria:

  • untreated hypothyroidism or hyperthyroidism
  • present or past malignant diseases
  • clinical liver disease
  • treatment with drugs known to interfere with bone metabolism (e.g. glucocorticoids)
Layout table for additonal information
Responsible Party: MD, Dr. Med. Sci Claus Gravholt, University of Aarhus Identifier: NCT00625001    
Other Study ID Numbers: 1994/2424
First Posted: February 28, 2008    Key Record Dates
Last Update Posted: February 28, 2008
Last Verified: February 2008
Keywords provided by University of Aarhus:
Turner Syndrome
bone mineral density
estrogen replacement therapy
dual energy x-ray absorptiometry
Additional relevant MeSH terms:
Layout table for MeSH terms
Turner Syndrome
Gonadal Dysgenesis
Pathologic Processes
Disorders of Sex Development
Urogenital Abnormalities
Sex Chromosome Disorders of Sex Development
Heart Defects, Congenital
Cardiovascular Abnormalities
Cardiovascular Diseases
Heart Diseases
Congenital Abnormalities
Sex Chromosome Disorders
Chromosome Disorders
Genetic Diseases, Inborn
Gonadal Disorders
Endocrine System Diseases